Method for determining the mortality risk

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes methods for predicting an individual's overall mortality risk by measuring the expression or activity of the AGXT2 gene/enzyme, or by detecting specific genetic variations (SNPs) in the AGXT2 gene. Low levels of AGXT2 or certain genetic alterations are linked with higher concentrations of SDMA, a molecule associated with increased risk of death, particularly after cardiovascular events like stroke. The invention also covers screening and use of compounds that can increase AGXT2 expression or activity, with the goal of reducing mortality risk.

Use CasesContent extracted from patent full text and abstract with AI.

• Risk assessment for long-term survival in patients who have experienced a stroke or cardiovascular event.
• Development of diagnostic tests to screen individuals for high all-cause mortality risk using blood samples.
• Genetic screening for identifying individuals carrying AGXT2 variants associated with increased mortality risk.
• Personalized medicine: tailoring treatments and monitoring strategies based on predicted individual mortality risk.
• Discovery and development of therapeutic compounds that enhance AGXT2 activity/expression to reduce mortality risk.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables early identification of patients at higher risk of mortality, allowing for proactive interventions.
• Supports more accurate and personalized risk stratification after cardiovascular events, which can improve clinical outcomes.
• Facilitates targeted preventive and therapeutic strategies based on a patient’s genetic and biochemical profile.
• Potential to decrease mortality risk through new drugs or supplements that boost AGXT2 activity.
• Uses established laboratory methods (e.g., PCR, ELISA, mass spectrometry) compatible with current clinical workflows.
• Provides biomarkers (gene expression, enzyme activity, genetic variants, SDMA levels) for robust and multifaceted risk assessment.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention generally relates to methods for determining the mortality risk in a subject. In one aspect, the invention relates to a method for determining/predicting the all-cause mortality risk of a test subject based on the detection of pathologically decreased expression levels of the gene encoding the alanine-glyoxylate-aminotransferase 2 (AGXT2) and/or pathologically decreased activity levels of the AGXT2 enzyme. In a further aspect, the invention relates to a method for determining/predicting the all-cause mortality risk of a test subject based on the detection of genetic alterations which are associated with such pathologically decreased expression levels and/or activity levels. Finally, the invention also relates to compounds which are effective in increasing the expression of the AGXT2 gene and/or the activity of the AGXT2 enzyme for use in a method of decreasing the mortality risk of a subject.